Otamixaban
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Otamixaban
- DrugBank Accession Number
- DB06635
- Background
Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 446.4983
Monoisotopic: 446.19540534 - Chemical Formula
- C25H26N4O4
- Synonyms
- Otamixaban
- External IDs
- FXV-673
- RPR-130673
- RPR130673
- XRP-0673
- XRP0673
Pharmacology
- Indication
Investigated for use/treatment in thrombosis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism UCoagulation factor X Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of bleeding can be increased when Abciximab is combined with Otamixaban. Aceclofenac The risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Otamixaban. Acemetacin The risk or severity of bleeding and hemorrhage can be increased when Otamixaban is combined with Acemetacin. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Otamixaban. Acetylsalicylic acid Acetylsalicylic acid may increase the anticoagulant activities of Otamixaban. - Food Interactions
- Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Otamixaban Hydrochloride WL9J31M2HI 409081-12-5 ROKCPUOLRIBSQQ-BYYQELCVSA-N
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenylpyridines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyridine ring through a CC or CN bond.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Pyridines and derivatives
- Sub Class
- Phenylpyridines
- Direct Parent
- Phenylpyridines
- Alternative Parents
- Beta amino acids and derivatives / Benzamides / Benzoyl derivatives / Fatty acid esters / Pyridinium derivatives / Methyl esters / Heteroaromatic compounds / Secondary carboxylic acid amides / Azacyclic compounds / Monocarboxylic acids and derivatives show 6 more
- Substituents
- 4-phenylpyridine / Amidine / Aromatic heteromonocyclic compound / Azacycle / Benzamide / Benzenoid / Benzoic acid or derivatives / Benzoyl / Beta amino acid or derivatives / Carbonyl group show 20 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- S173RED00L
- CAS number
- 193153-04-7
- InChI Key
- PFGVNLZDWRZPJW-OPAMFIHVSA-N
- InChI
- InChI=1S/C25H26N4O4/c1-16(22(25(31)33-2)15-17-4-3-5-21(14-17)23(26)27)28-24(30)20-8-6-18(7-9-20)19-10-12-29(32)13-11-19/h3-14,16,22H,15H2,1-2H3,(H3,26,27)(H,28,30)/t16-,22-/m1/s1
- IUPAC Name
- 4-(4-{[(2R,3R)-3-[(3-carbamimidoylphenyl)methyl]-4-methoxy-4-oxobutan-2-yl]carbamoyl}phenyl)pyridin-1-ium-1-olate
- SMILES
- COC(=O)[C@H](CC1=CC(=CC=C1)C(N)=N)[C@@H](C)NC(=O)C1=CC=C(C=C1)C1=CC=[N+]([O-])C=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 5496659
- ChemSpider
- 4593439
- BindingDB
- 50114539
- ChEMBL
- CHEMBL46618
- ZINC
- ZINC000001908051
- Wikipedia
- Otamixaban
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Acute Coronary Syndrome (ACS) 1 2 Completed Treatment Angioplasty, Transluminal, Percutaneous Coronary 1 2 Completed Treatment Coronary Heart Disease (CHD) 1 1 Completed Basic Science Impaired Renal Function 1 1 Completed Treatment Hepatic Impairment 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00202 mg/mL ALOGPS logP 2.12 ALOGPS logP 0.78 Chemaxon logS -5.4 ALOGPS pKa (Strongest Acidic) 15.03 Chemaxon pKa (Strongest Basic) 11.46 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 132.21 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 137.24 m3·mol-1 Chemaxon Polarizability 48.13 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.5326 Blood Brain Barrier + 0.9199 Caco-2 permeable - 0.591 P-glycoprotein substrate Non-substrate 0.5454 P-glycoprotein inhibitor I Non-inhibitor 0.9186 P-glycoprotein inhibitor II Non-inhibitor 0.7824 Renal organic cation transporter Non-inhibitor 0.8502 CYP450 2C9 substrate Non-substrate 0.7351 CYP450 2D6 substrate Non-substrate 0.8129 CYP450 3A4 substrate Non-substrate 0.5141 CYP450 1A2 substrate Non-inhibitor 0.7534 CYP450 2C9 inhibitor Non-inhibitor 0.6407 CYP450 2D6 inhibitor Non-inhibitor 0.8638 CYP450 2C19 inhibitor Non-inhibitor 0.6357 CYP450 3A4 inhibitor Non-inhibitor 0.9066 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8028 Ames test Non AMES toxic 0.5202 Carcinogenicity Non-carcinogens 0.8271 Biodegradation Not ready biodegradable 0.8529 Rat acute toxicity 2.6725 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9975 hERG inhibition (predictor II) Non-inhibitor 0.7187
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 205.0357 predictedDeepCCS 1.0 (2019) [M+H]+ 207.43129 predictedDeepCCS 1.0 (2019) [M+Na]+ 213.315 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCoagulation factor X
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
- Gene Name
- F10
- Uniprot ID
- P00742
- Uniprot Name
- Coagulation factor X
- Molecular Weight
- 54731.255 Da
References
- Ahrens I, Peter K, Bode C: [Factor Xa-inhibition in interventional cardiology]. Hamostaseologie. 2007 Dec;27(5):328-32. [Article]
- Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U: Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor. Thromb Haemost. 2005 Dec;94(6):1156-63. [Article]
Drug created at March 19, 2008 16:42 / Updated at February 21, 2021 18:52